Morgan Stanley Immunity Bio, Inc. Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,246,892 shares of IBRX stock, worth $5.89 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,246,892
Previous 568,401
295.3%
Holding current value
$5.89 Million
Previous $3.59 Million
132.04%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding IBRX
# of Institutions
204Shares Held
70MCall Options Held
1.68MPut Options Held
1.31M-
Vanguard Group Inc Valley Forge, PA16.9MShares$44.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$29.9 Million0.0% of portfolio
-
State Street Corp Boston, MA8.65MShares$22.7 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.85MShares$10.1 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.07MShares$5.42 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $1.05B
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...